| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Active Surveillance for Localized Small Renal Masses: Current Perspectives
|
Campbell, Steven C.
|
|
|
|
3 |
p. 188-189
|
artikel
|
| 2 |
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients
|
Soeterik, Timo F.W.
|
|
|
|
3 |
p. 231-237
|
artikel
|
| 3 |
Adaptive Immunity in Genitourinary Cancers
|
Koti, Madhuri
|
|
|
|
3 |
p. 263-272
|
artikel
|
| 4 |
Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics
|
Msaouel, Pavlos
|
|
|
|
3 |
p. 265-267
|
artikel
|
| 5 |
Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide
|
Wallis, Christopher J.D.
|
|
|
|
3 |
p. 238-241
|
artikel
|
| 6 |
Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis
|
Cao, Brent
|
|
|
|
3 |
p. 237-250
|
artikel
|
| 7 |
All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others
|
Emmett, Louise
|
|
|
|
3 |
p. 283-284
|
artikel
|
| 8 |
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
|
McGregor, Bradley
|
|
|
|
3 |
p. 339-348
|
artikel
|
| 9 |
A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk
|
Miah, Saiful
|
|
|
|
3 |
p. 262-269
|
artikel
|
| 10 |
An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study
|
Eldred-Evans, David
|
|
|
|
3 |
p. 295-302
|
artikel
|
| 11 |
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
|
Khaki, Ali Raza
|
|
|
|
3 |
p. 464-472
|
artikel
|
| 12 |
A New Twist to an Old Tale: Immunotherapy in Non–muscle-invasive Bladder Cancer
|
Funt, Samuel A.
|
|
|
|
3 |
p. 199-201
|
artikel
|
| 13 |
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non–muscle-invasive Bladder Cancer
|
Inman, Brant A.
|
|
|
|
3 |
p. 313-320
|
artikel
|
| 14 |
Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma
|
Khene, Zine-Eddine
|
|
|
|
3 |
p. 323-330
|
artikel
|
| 15 |
A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research
|
Bates, Anthony S.
|
|
|
|
3 |
p. 405-423
|
artikel
|
| 16 |
A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer
|
Grobet-Jeandin, Elisabeth
|
|
|
|
3 |
p. 251-262
|
artikel
|
| 17 |
A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease
|
Erickson, Andrew
|
|
|
|
3 |
p. 358-369
|
artikel
|
| 18 |
A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer
|
Ventimiglia, Eugenio
|
|
|
|
3 |
p. 294-301
|
artikel
|
| 19 |
Can the Use of Serial Multiparametric Magnetic Resonance Imaging During Active Surveillance of Prostate Cancer Avoid the Need for Prostate Biopsies?—A Systematic Diagnostic Test Accuracy Review
|
Hettiarachchi, Dinul
|
|
|
|
3 |
p. 426-436
|
artikel
|
| 20 |
Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer
|
Panebianco, Valeria
|
|
|
|
3 |
p. 208-214
|
artikel
|
| 21 |
Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer
|
Gregg, Justin R.
|
|
|
|
3 |
p. 282-288
|
artikel
|
| 22 |
Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology
|
Kalapara, Arveen A.
|
|
|
|
3 |
p. 314-320
|
artikel
|
| 23 |
Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer
|
Lughezzani, Giovanni
|
|
|
|
3 |
p. 329-332
|
artikel
|
| 24 |
Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies
|
van der Kwast, Theo H.
|
|
|
|
3 |
p. 333-336
|
artikel
|
| 25 |
Contemporary Imaging Technologies for Men with Rising Prostate-specific Antigen After Radical Prostatectomy and Before Early Salvage Irradiation: Where Do We Stand?
|
Bossi, Alberto
|
|
|
|
3 |
p. 356-357
|
artikel
|
| 26 |
Contents
|
|
|
|
|
3 |
p. iii-v
|
artikel
|
| 27 |
Contents
|
|
|
|
|
3 |
p. iii-v
|
artikel
|
| 28 |
Contents
|
|
|
|
|
3 |
p. iii-v
|
artikel
|
| 29 |
Contents
|
|
|
|
|
3 |
p. iii-iv
|
artikel
|
| 30 |
Contents
|
|
|
|
|
3 |
p. iii-v
|
artikel
|
| 31 |
Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations
|
Gandellini, Paolo
|
|
|
|
3 |
p. 277-285
|
artikel
|
| 32 |
Corrigendum to ‘Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)’ [European Urology Oncology 3 (2021) 256–263]
|
Marchioni, Michele
|
|
|
|
3 |
p. 517
|
artikel
|
| 33 |
Corrigendum to ‘The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy’ [European Urology Oncology 1 (2018) 263–267]
|
Patel, Neal
|
|
|
|
3 |
p. 394
|
artikel
|
| 34 |
Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma
|
Mason, Neil T.
|
|
|
|
3 |
p. 331-338
|
artikel
|
| 35 |
COVID-19 and Bacillus Calmette-Guérin: What is the Link?
|
Hegarty, Paul K.
|
|
|
|
3 |
p. 259-261
|
artikel
|
| 36 |
Data-driven Focal Therapy for Localized Prostate Cancer: A Wake-up Call
|
Shah, Ankeet
|
|
|
|
3 |
p. 424-425
|
artikel
|
| 37 |
Defining Risk Categories for a Significant Decline in Estimated Glomerular Filtration Rate After Robotic Partial Nephrectomy: Implications for Patient Follow-up
|
Martini, Alberto
|
|
|
|
3 |
p. 498-501
|
artikel
|
| 38 |
Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy
|
Bravi, Carlo A.
|
|
|
|
3 |
p. 285-295
|
artikel
|
| 39 |
Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer
|
Brastianos, Harry C.
|
|
|
|
3 |
p. 362-365
|
artikel
|
| 40 |
Development and External Validation of a Novel Nomogram to Predict Side-specific Extraprostatic Extension in Patients with Prostate Cancer Undergoing Radical Prostatectomy
|
Soeterik, Timo F.W.
|
|
|
|
3 |
p. 328-337
|
artikel
|
| 41 |
Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer
|
Akamatsu, Shusuke
|
|
|
|
3 |
p. 320-328
|
artikel
|
| 42 |
Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
|
Woo, Sungmin
|
|
|
|
3 |
p. 306-315
|
artikel
|
| 43 |
Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?
|
Burger, Maximilian
|
|
|
|
3 |
p. 510-514
|
artikel
|
| 44 |
Editorial Board
|
|
|
|
|
3 |
p. i-ii
|
artikel
|
| 45 |
Editorial Board
|
|
|
|
|
3 |
p. i-ii
|
artikel
|
| 46 |
Editorial Board
|
|
|
|
|
3 |
p. i-ii
|
artikel
|
| 47 |
Editorial Board
|
|
|
|
|
3 |
p. iii-vi
|
artikel
|
| 48 |
Editorial Board
|
|
|
|
|
3 |
p. i-ii
|
artikel
|
| 49 |
Editorial Board
|
|
|
|
|
3 |
p. i-ii
|
artikel
|
| 50 |
Editorial Board
|
|
|
|
|
3 |
p. i-ii
|
artikel
|
| 51 |
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
|
Lalani, Aly-Khan A.
|
|
|
|
3 |
p. 372-381
|
artikel
|
| 52 |
Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer
|
Vázquez, Ramiro
|
|
|
|
3 |
p. 437-446
|
artikel
|
| 53 |
Estimating the Effectiveness of Kidney Cancer Screening Within Lung Cancer Screening Programmes: A Validation in UK Biobank
|
Harrison, Hannah
|
|
|
|
3 |
p. 351-353
|
artikel
|
| 54 |
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non–muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis
|
Kamat, Ashish M.
|
|
|
|
3 |
p. 318-340
|
artikel
|
| 55 |
Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action
|
Bhanvadia, Sumeet K.
|
|
|
|
3 |
p. 396-404
|
artikel
|
| 56 |
[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature
|
Evangelista, Laura
|
|
|
|
3 |
p. 273-282
|
artikel
|
| 57 |
GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture
|
Jeyapala, Renu
|
|
|
|
3 |
p. 231-238
|
artikel
|
| 58 |
Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature
|
Aragaki, Adam K.
|
|
|
|
3 |
p. 338-346
|
artikel
|
| 59 |
Health-related Quality of Life and Cost Effectiveness of Treatment: Components to Be Included in Clinical Decision-making
|
Bergerot, Cristiane Decat
|
|
|
|
3 |
p. 349-350
|
artikel
|
| 60 |
Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care
|
Lawson, Keith A.
|
|
|
|
3 |
p. 494-497
|
artikel
|
| 61 |
How to Select the Optimal Candidates for Renal Mass Biopsy
|
Martini, Alberto
|
|
|
|
3 |
p. 506-509
|
artikel
|
| 62 |
Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review
|
Williams, Stephen B.
|
|
|
|
3 |
p. 265-273
|
artikel
|
| 63 |
Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes
|
Hensley, Patrick J.
|
|
|
|
3 |
p. 347-356
|
artikel
|
| 64 |
Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy
|
Campbell, Shauna R.
|
|
|
|
3 |
p. 304-313
|
artikel
|
| 65 |
Intermediate-risk Prostate Cancer: Stratification and Management
|
Preisser, Felix
|
|
|
|
3 |
p. 270-280
|
artikel
|
| 66 |
In the Age of Immunotherapy, How Can We Translate the CARMENA Results into Practice?
|
Yekedüz, Emre
|
|
|
|
3 |
p. 515-516
|
artikel
|
| 67 |
Key Prerequisites for the Correct Management of Intermediate-risk Prostate Cancer
|
Montorsi, Francesco
|
|
|
|
3 |
p. 281-282
|
artikel
|
| 68 |
Leveraging the Tumor Immune Microenvironment To Overcome Genitourinary Cancers
|
Bellone, Matteo
|
|
|
|
3 |
p. 273-274
|
artikel
|
| 69 |
Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion
|
Gorovets, Daniel
|
|
|
|
3 |
p. 275-281
|
artikel
|
| 70 |
Management of Prostate Cancer Patients with Clinically Positive Lymph Nodes
|
Gillessen, Silke
|
|
|
|
3 |
p. 302-303
|
artikel
|
| 71 |
Managing Discordant Findings Between Multiparametric Magnetic Resonance Imaging and Transrectal Magnetic Resonance Imaging–directed Prostate Biopsy—The Key Role of Magnetic Resonance Imaging–directed Transperineal Biopsy
|
Bajeot, Anne-Sophie
|
|
|
|
3 |
p. 296-303
|
artikel
|
| 72 |
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer
|
Deek, Matthew P.
|
|
|
|
3 |
p. 447-455
|
artikel
|
| 73 |
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2–4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials
|
Bandini, Marco
|
|
|
|
3 |
p. 248-256
|
artikel
|
| 74 |
Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes
|
Ruan, Jia-Ling
|
|
|
|
3 |
p. 239-247
|
artikel
|
| 75 |
Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging
|
Truong, Matthew
|
|
|
|
3 |
p. 257-264
|
artikel
|
| 76 |
Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma
|
Hoerner, Christian R.
|
|
|
|
3 |
p. 360-364
|
artikel
|
| 77 |
National Norwegian Practice Patterns for Surgical Treatment of Kidney Cancer Tumors ≤7cm: Adherence to Changes in Guidelines May Improve Overall Survival
|
Hjelle, Karin M.
|
|
|
|
3 |
p. 252-261
|
artikel
|
| 78 |
National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004–2013
|
Bateni, Zhoobin H.
|
|
|
|
3 |
p. 343-350
|
artikel
|
| 79 |
Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study
|
Loubersac, Thomas
|
|
|
|
3 |
p. 298-305
|
artikel
|
| 80 |
Oncological and Functional Outcomes for Men Undergoing Salvage Whole-gland Cryoablation for Radiation-resistant Prostate Cancer
|
Tan, Wei Phin
|
|
|
|
3 |
p. 289-294
|
artikel
|
| 81 |
Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort
|
Blazevski, Alexandar
|
|
|
|
3 |
p. 283-290
|
artikel
|
| 82 |
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review
|
Lotan, Yair
|
|
|
|
3 |
p. 223-230
|
artikel
|
| 83 |
Patient Experience of Systematic Versus Fusion Prostate Biopsies
|
Eineluoto, Juho T.
|
|
|
|
3 |
p. 202-207
|
artikel
|
| 84 |
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era
|
Bellmunt, Joaquim
|
|
|
|
3 |
p. 502-505
|
artikel
|
| 85 |
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
|
Grivas, Petros
|
|
|
|
3 |
p. 351-359
|
artikel
|
| 86 |
Personalized Follow-up in Clinical Stage I Testicular Germ Cell Tumors: The Future is Beginning
|
Heidenreich, Axel
|
|
|
|
3 |
p. 492-493
|
artikel
|
| 87 |
Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes
|
Woldu, Solomon L.
|
|
|
|
3 |
p. 242-251
|
artikel
|
| 88 |
Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7–10 Prostate Cancer in Biopsy-naïve Men
|
Boesen, Lars
|
|
|
|
3 |
p. 311-319
|
artikel
|
| 89 |
Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men
|
Chandrasekar, Thenappan
|
|
|
|
3 |
p. 291-297
|
artikel
|
| 90 |
PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer
|
Steuber, Thomas
|
|
|
|
3 |
p. 321-327
|
artikel
|
| 91 |
Re: Armando Stabile, Antony Pellegrino, Elio Mazzone, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur Urol Oncol 2022;5:1–17
|
Chen, Kenneth
|
|
|
|
3 |
p. 375-376
|
artikel
|
| 92 |
Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417–27
|
Massari, Francesco
|
|
|
|
3 |
p. 340-341
|
artikel
|
| 93 |
Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353–66
|
Di Nunno, Vincenzo
|
|
|
|
3 |
p. 390
|
artikel
|
| 94 |
Re: Lars Boesen, Nis Nørgaard, Vibeke Løgager, et al. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7–10 Prostate Cancer in Biopsy-naïve Men. Eur Urol Oncol 2019;2:311–9
|
Morote, Juan
|
|
|
|
3 |
p. 392-393
|
artikel
|
| 95 |
Reply from Authors re: Peter Albers. Volume Matters: Can We Rely on the Evidence? Eur Urol Oncol 2019;2:274–5
|
Williams, Stephen B.
|
|
|
|
3 |
p. 276
|
artikel
|
| 96 |
Re: Shusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2019;2:320–328
|
Mazzone, Elio
|
|
|
|
3 |
p. 338-339
|
artikel
|
| 97 |
Re: Thomas Loubersac, Molière Nguile-Makao, Frédéric Pouliot, Vincent Fradet, Paul Toren. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. Eur Urol Oncol 2020;3:298–305
|
Yasri, Sora
|
|
|
|
3 |
p. 391
|
artikel
|
| 98 |
Re: Tom A. Hueting, Erik B. Cornel, Diederik M. Somford, et al. External Validation of Models Predicting the Probability of Lymph Node Involvement in Prostate Cancer Patients. Eur Urol Oncol 2018;1:411–7
|
Gandaglia, Giorgio
|
|
|
|
3 |
p. 337
|
artikel
|
| 99 |
Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505–16
|
Montorsi, Francesco
|
|
|
|
3 |
p. 354
|
artikel
|
| 100 |
Role of Active Surveillance for Localized Small Renal Masses
|
Mir, Maria Carmen
|
|
|
|
3 |
p. 177-187
|
artikel
|
| 101 |
Role of Checkpoint Inhibition in Localized Bladder Cancer
|
Hahn, Noah M.
|
|
|
|
3 |
p. 190-198
|
artikel
|
| 102 |
Salvage Reirradiation Options for Treating Local Recurrence After Previous Prostatectomy and Radiotherapy: Where Do We Stand?
|
Zhong, Jim
|
|
|
|
3 |
p. 311-312
|
artikel
|
| 103 |
Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter Study
|
Archer, Paul
|
|
|
|
3 |
p. 303-310
|
artikel
|
| 104 |
Staging 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer
|
Voskuilen, Charlotte S.
|
|
|
|
3 |
p. 366-369
|
artikel
|
| 105 |
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group
|
Gerdtsson, Axel
|
|
|
|
3 |
p. 382-389
|
artikel
|
| 106 |
Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor–based Dual Combination Therapy
|
Graafland, Niels M.
|
|
|
|
3 |
p. 373-374
|
artikel
|
| 107 |
The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients
|
Bandini, Marco
|
|
|
|
3 |
p. 215-222
|
artikel
|
| 108 |
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery—Results from RECUR Consortium
|
Abu-Ghanem, Yasmin
|
|
|
|
3 |
p. 473-482
|
artikel
|
| 109 |
The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy
|
Martini, Alberto
|
|
|
|
3 |
p. 370-372
|
artikel
|
| 110 |
The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities
|
Ghali, Fady
|
|
|
|
3 |
p. 321-322
|
artikel
|
| 111 |
The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature
|
Abrams-Pompe, Raisa S.
|
|
|
|
3 |
p. 370-395
|
artikel
|
| 112 |
Three-dimensional Magnetic Resonance Imaging–based Printed Models of Prostate Anatomy and Targeted Biopsy-proven Index Tumor to Facilitate Patient-tailored Radical Prostatectomy—A Feasibility Study
|
Darr, Christopher
|
|
|
|
3 |
p. 357-361
|
artikel
|
| 113 |
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
|
Szabados, Bernadett
|
|
|
|
3 |
p. 456-463
|
artikel
|
| 114 |
Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study
|
Weiner, Adam B.
|
|
|
|
3 |
p. 304-310
|
artikel
|
| 115 |
Unanswered Questions for Bladder Tumours Unresponsive to Bacillus Calmette-Guérin
|
Babjuk, Marko
|
|
|
|
3 |
p. 341-342
|
artikel
|
| 116 |
Urologists, You’ll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non–muscle-invasive Bladder Cancer
|
Giannarini, Gianluca
|
|
|
|
3 |
p. 268-272
|
artikel
|
| 117 |
Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review
|
Valle, Luca
|
|
|
|
3 |
p. 339-355
|
artikel
|
| 118 |
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign
|
Li, Roger
|
|
|
|
3 |
p. 286-293
|
artikel
|
| 119 |
Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer
|
Lobo, João
|
|
|
|
3 |
p. 483-491
|
artikel
|
| 120 |
Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity
|
Vilaseca, Antoni
|
|
|
|
3 |
p. 365-371
|
artikel
|
| 121 |
Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery?
|
van der Heijden, Antoine G.
|
|
|
|
3 |
p. 316-317
|
artikel
|
| 122 |
Volume Matters: Can We Rely on the Evidence?
|
Albers, Peter
|
|
|
|
3 |
p. 274-275
|
artikel
|
Tijdschrift beschrijving